Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2014

01.09.2014 | Original Article – Cancer Research

Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe 18F-FBEM–Cys39-exendin-4

verfasst von: Yuping Xu, Donghui Pan, Qing Xu, Chen Zhu, Lizhen Wang, Fei Chen, Runlin Yang, Shineng Luo, Min Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glucagon-like peptide-1 receptor (GLP-1R) is a specific target for insulinomas imaging since it is overexpressed in the tumor. Exendin-4 exhibits high affinity for the GLP-1R. In this study, a novel 18F-labeled exendin-4 analog, 18F-FBEM–Cys39-exendin-4, was synthesized and its potentials for GLP-1R imaging were also evaluated.

Methods

18F-FBEM was synthesized by coupling 18F-fluorobenzoic acid (18F-FBA) with N-(2-aminoethyl) maleimide, and the reaction conditions were optimized. Cys39-exendin-4 was then conjugated with 18F-FBEM to obtain 18F-FBEM–Cys39-exendin-4. The GLP-1R targeting potential and pharmacokinetic profile of the tracer were analyzed in INS-1 insulinoma and MDA-MB-435 breast tumor model, respectively.

Results

Under the optimal conditions, the yield of radiolabeled 18F-FBEM was 49.1 ± 2.0 % (based on 18F-FBA, non-decay corrected). The yield of 18F-FBEM–Cys39-exendin-4 was 35.1 ± 2.6 % (based on the starting 18F-FBEM, non-decay corrected). The radiochemical purity of 18F-FBEM–Cys39-exendin-4 is >95 %, and the specific activity was at least 35 GBq/μmol. The GLP-1R-positive INS-1 insulinoma xenograft was clearly visible with good contrast to background, whereas GLP-1R-negative MDA-MB435 breast tumor was barely visible. Low levels of radioactivity were also detected at pancreas and lungs due to few GLP-1R expressions. GLP-1R binding specificity was demonstrated by reduced INS-1 tumor uptake of the tracer after coinjection with an excess of unlabeled Cys39-exendin-4 at 1 h postinjection.

Conclusion

The thiol-reactive reagent, 18F-FBEM, was prepared with high yield and successfully conjugated to Cys39-exendin-4. Favorable preclinical data showing specific and effective tumor targeting by 18F-FBEM–Cys39-exendin-4 suggest that the tracer may be a potential probe for insulinomas imaging.
Literatur
Zurück zum Zitat Ambrosini V, Fani M, Fanti S et al (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42S–55SPubMedCrossRef Ambrosini V, Fani M, Fanti S et al (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42S–55SPubMedCrossRef
Zurück zum Zitat Cai W, Zhang X, Wu Y et al (2006) A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 47:1172–1180PubMedCentralPubMed Cai W, Zhang X, Wu Y et al (2006) A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 47:1172–1180PubMedCentralPubMed
Zurück zum Zitat Chatziioannou A, Kehagias D, Mourikis D et al (2001) Imaging and localization of pancreatic insulinomas. Clin Imaging 25:275–283PubMedCrossRef Chatziioannou A, Kehagias D, Mourikis D et al (2001) Imaging and localization of pancreatic insulinomas. Clin Imaging 25:275–283PubMedCrossRef
Zurück zum Zitat Christ E, Wild D, Forrer F et al (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398–4405PubMedCrossRef Christ E, Wild D, Forrer F et al (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398–4405PubMedCrossRef
Zurück zum Zitat Doyle ME, Theodorakis MJ, Holloway HW et al (2003) The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114:153–158PubMedCrossRef Doyle ME, Theodorakis MJ, Holloway HW et al (2003) The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114:153–158PubMedCrossRef
Zurück zum Zitat Gotthardt M, Fischer M, Naeher I et al (2002) Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 29:597–606PubMed Gotthardt M, Fischer M, Naeher I et al (2002) Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 29:597–606PubMed
Zurück zum Zitat Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52:56S–63SPubMedCrossRef Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52:56S–63SPubMedCrossRef
Zurück zum Zitat Kiesewetter DO, Jacobson O, Lang L et al (2011) Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot 69:410–414PubMedCentralPubMedCrossRef Kiesewetter DO, Jacobson O, Lang L et al (2011) Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot 69:410–414PubMedCentralPubMedCrossRef
Zurück zum Zitat Kiesewetter DO, Gao H, Ma Y et al (2012) 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 39:463–473PubMedCentralPubMed Kiesewetter DO, Gao H, Ma Y et al (2012) 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging 39:463–473PubMedCentralPubMed
Zurück zum Zitat Körner M, Stöckli M, Waser B et al (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736–743PubMedCrossRef Körner M, Stöckli M, Waser B et al (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48:736–743PubMedCrossRef
Zurück zum Zitat Körner M, Christ E, Wild D et al (2012) Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne) 3:158 Körner M, Christ E, Wild D et al (2012) Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne) 3:158
Zurück zum Zitat Lütje S, Boerman OC, van Rij CM et al (2012) Prospects in radionuclide imaging of prostate cancer. Prostate 72:1262–1272PubMedCrossRef Lütje S, Boerman OC, van Rij CM et al (2012) Prospects in radionuclide imaging of prostate cancer. Prostate 72:1262–1272PubMedCrossRef
Zurück zum Zitat Norton JA (2006) Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10:327–331PubMedCrossRef Norton JA (2006) Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10:327–331PubMedCrossRef
Zurück zum Zitat Pan DH, Yan RH, Xu YP, Pan D, Yan Y, Yang R, Xu Y, Chen F, Wang L, Luo S, Yang M et al (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol I. doi:10.1002/cmmi.1583 Pan DH, Yan RH, Xu YP, Pan D, Yan Y, Yang R, Xu Y, Chen F, Wang L, Luo S, Yang M et al (2014) PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol I. doi:10.​1002/​cmmi.​1583
Zurück zum Zitat Parry JJ, Kelly TS, Andrews R et al (2007) In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7–14) analogues containing different amino acid linker moieties. Bioconjug Chem 18:1110–1117PubMedCrossRef Parry JJ, Kelly TS, Andrews R et al (2007) In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7–14) analogues containing different amino acid linker moieties. Bioconjug Chem 18:1110–1117PubMedCrossRef
Zurück zum Zitat Pery C, Meurette G, Ansquer C et al (2010) Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 34:465–474PubMedCrossRef Pery C, Meurette G, Ansquer C et al (2010) Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 34:465–474PubMedCrossRef
Zurück zum Zitat Ramage JK, Davies AH, Ardill J et al (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54:iv1–iv16PubMedCentralPubMedCrossRef Ramage JK, Davies AH, Ardill J et al (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54:iv1–iv16PubMedCentralPubMedCrossRef
Zurück zum Zitat Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793PubMed Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793PubMed
Zurück zum Zitat Sowa-Staszczak A, Pach D, Mikołajczak R et al (2013) Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 40:524–531PubMedCentralPubMed Sowa-Staszczak A, Pach D, Mikołajczak R et al (2013) Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 40:524–531PubMedCentralPubMed
Zurück zum Zitat Wang Y, Lim K, Normandin M et al (2012a) Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass. Nucl Med Biol 39:167–176PubMedCrossRef Wang Y, Lim K, Normandin M et al (2012a) Synthesis and evaluation of [18F]exendin (9–39) as a potential biomarker to measure pancreatic β-cell mass. Nucl Med Biol 39:167–176PubMedCrossRef
Zurück zum Zitat Wang H, Gao H, Guo N et al (2012b) Site-specific labeling of scVEGF with fluorine-18 for positron emission tomography imaging. Theranostics 2:607–617PubMedCentralPubMedCrossRef Wang H, Gao H, Guo N et al (2012b) Site-specific labeling of scVEGF with fluorine-18 for positron emission tomography imaging. Theranostics 2:607–617PubMedCentralPubMedCrossRef
Zurück zum Zitat Wicki A, Wild D, Storch D et al (2007) [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 13:3696–3705PubMedCrossRef Wicki A, Wild D, Storch D et al (2007) [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 13:3696–3705PubMedCrossRef
Zurück zum Zitat Wiesli P, Brandle M, Schmid C et al (2004) Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol 15:1251–1256PubMedCrossRef Wiesli P, Brandle M, Schmid C et al (2004) Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol 15:1251–1256PubMedCrossRef
Zurück zum Zitat Wild D, Béhé M, Wicki A et al (2006) Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025–2033PubMed Wild D, Béhé M, Wicki A et al (2006) Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025–2033PubMed
Zurück zum Zitat Wild D, Wicki A, Mansi R et al (2010) Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51:1059–1067PubMedCrossRef Wild D, Wicki A, Mansi R et al (2010) Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51:1059–1067PubMedCrossRef
Zurück zum Zitat Wild D, Christ E, Caplin ME et al (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 51:1073–1078CrossRef Wild D, Christ E, Caplin ME et al (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 51:1073–1078CrossRef
Zurück zum Zitat Wu Z, Liu S, Hassink M et al (2013) Development and evaluation of 18F-TTCO-Cys40-exendin-4: a PET probe for imaging transplanted islets. J Nucl Med 54:244–251PubMedCrossRef Wu Z, Liu S, Hassink M et al (2013) Development and evaluation of 18F-TTCO-Cys40-exendin-4: a PET probe for imaging transplanted islets. J Nucl Med 54:244–251PubMedCrossRef
Zurück zum Zitat Yue X, Kiesewetter DO, Guo J et al (2013) Development of a new thiol site-specific prosthetic group and Its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas. Bioconjug Chem 24:1191–1200PubMedCentralPubMedCrossRef Yue X, Kiesewetter DO, Guo J et al (2013) Development of a new thiol site-specific prosthetic group and Its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas. Bioconjug Chem 24:1191–1200PubMedCentralPubMedCrossRef
Metadaten
Titel
Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe 18F-FBEM–Cys39-exendin-4
verfasst von
Yuping Xu
Donghui Pan
Qing Xu
Chen Zhu
Lizhen Wang
Fei Chen
Runlin Yang
Shineng Luo
Min Yang
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1701-8

Weitere Artikel der Ausgabe 9/2014

Journal of Cancer Research and Clinical Oncology 9/2014 Zur Ausgabe

Review – Cancer Research

The role of miR-148a in gastric cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.